Amgen Achieves A First With European Eculizumab Nod
Bekemv Biosimilar Rival To Soliris Receives Positive Opinion From EMA’s CHMP
Amgen has received a positive opinion from the EMA’s CHMP recommending that its Bekemv eculizumab biosimilar become the first Soliris rival to be granted a pan-European marketing authorization.
